PEPG (PepGen Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by PEPG officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-22 | Habib J Dable | Director | A | — | — |
| 2026-06-22 | LAURIE KEATING | Director | A | — | — |
| 2026-06-22 | Howard Mayer | Director | A | — | — |
| 2026-06-22 | Lisa Wyman | Director | A | — | — |
| 2026-06-22 | Joshua Resnick | Director | A | — | — |
| 2026-06-22 | Mitchell H. Finer | Director | A | — | — |
| 2026-06-22 | HEIDI HENSON | Director | A | — | — |
| 2026-06-22 | RA Capital Nexus Fund II, L.P. | Director | A | — | — |
| 2026-05-26 | Kasra Kasraian | Chief Technical Officer | Sell | — | — |
| 2026-03-06 | Noel Donnelly | Chief Financial Officer | Sell | — | — |
| 2026-03-06 | PAUL STRECK | EVP, Head of R&D | Sell | — | — |
| 2026-03-06 | James G McArthur | President and CEO | Sell | — | — |
| 2026-03-02 | Kasra Kasraian | Chief Technical Officer | A | — | — |
| 2026-03-02 | Noel Donnelly | Chief Financial Officer | A | — | — |
| 2026-03-02 | PAUL STRECK | EVP, Head of R&D | A | — | — |
| 2026-03-02 | Joseph Vittiglio | Chief Business & Legal Officer | A | — | — |
| 2026-03-02 | James G McArthur | President and CEO | A | — | — |
| 2025-12-18 | Noel Donnelly | Chief Financial Officer | MIXED | — | — |
| 2025-12-18 | PAUL STRECK | EVP, Head of R&D | MIXED | — | — |
| 2025-12-18 | James G McArthur | President and CEO | MIXED | — | — |
| 2025-12-10 | Joseph Vittiglio | Chief Business & Legal Officer | A | — | — |
| 2025-10-01 | Oxford Science Enterprises plc | — | Buy | — | — |
| 2025-09-30 | RA Capital Healthcare Fund LP | Director | Buy | — | — |
| 2025-06-06 | HEIDI HENSON | Director | A | — | — |
| 2025-06-06 | Howard Mayer | Director | A | — | — |
| 2025-06-06 | Joshua Resnick | Director | A | — | — |
| 2025-06-06 | LAURIE KEATING | Director | A | — | — |
| 2025-06-06 | Habib J Dable | Director | A | — | — |
| 2025-06-06 | RA Capital Nexus Fund II, L.P. | Director | A | — | — |
| 2025-06-02 | PAUL STRECK | EVP, Head of R&D | Buy | — | — |
| 2025-05-21 | Kasra Kasraian | Chief Technical Officer | A | — | — |
| 2025-04-22 | James G McArthur | President and CEO | Buy | — | — |
| 2025-04-09 | James G McArthur | President and CEO | Buy | — | — |
| 2025-03-31 | Mitchell H. Finer | Director | A | — | — |
| 2025-03-31 | Lisa Wyman | Director | A | — | — |
| 2025-03-05 | PAUL STRECK | EVP, Head of R&D | A | — | — |
| 2025-03-05 | Mary Beth DeLena | General Counsel | A | — | — |
| 2025-03-05 | Noel Donnelly | Chief Financial Officer | A | — | — |
| 2025-03-05 | James G McArthur | President and CEO | A | — | — |
| 2025-02-26 | Noel Donnelly | Chief Financial Officer | MIXED | — | — |
| 2025-02-26 | Mary Beth DeLena | General Counsel | MIXED | — | — |
| 2024-08-20 | PAUL STRECK | EVP, Head of R&D | A | — | — |
| 2024-07-26 | Michelle L Mellion | Chief Medical Officer | MIXED | — | — |
| 2024-07-19 | Michelle L Mellion | Chief Medical Officer | MIXED | — | — |
| 2024-07-16 | Michelle L Mellion | Chief Medical Officer | MIXED | — | — |
| 2024-07-03 | Michelle L Mellion | Chief Medical Officer | MIXED | — | — |
| 2024-06-26 | Michelle L Mellion | Chief Medical Officer | MIXED | — | — |
| 2024-06-21 | Joshua Resnick | Director | A | — | — |
| 2024-06-21 | Habib J Dable | Director | A | — | — |
| 2024-06-21 | Howard Mayer | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,955,388 | — |
| — | Director | 1,052,851 | — |
| — | 10%+ Owner | 476,813 | — |
| — | President and CEO | 296,326 | — |
| — | Director | 207,672 | — |
| — | Chief Financial Officer | 111,655 | — |
| — | EVP, Head of R&D | 76,226 | — |
| — | Chief Business & Legal Officer | 65,717 | — |
| — | Chief Technical Officer | 50,074 | — |
| — | General Counsel | 14,968 | — |
| — | Director | 4,166 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PEPG quote page; the site-wide leaderboard is on the insider transactions hub.